Citations

Clear

3501 citation(s) found for "Xu, Timothy".

Evaluation of advanced imaging biomarkers at kidney failure in patients with ADPKD: a pilot study
Wigerinck, Stijn , Gregory, Adriana , Iliuta, Ioan-Andrei, Hanna, Christian , Chedid, Maroun , Kaidbay, Hasan-Daniel N., Senum, Sarah R. , Shukoor, Shebaz, Harris, Peter C. , Kline, Timothy L. , Gregory, Adriana V, Harris, Peter C , Hanna, Christian , Senum, Sarah R , Smith, Byron H. , Torres, Vicente E. , Chebib, Fouad T.

Mayo Clinic

Clinical Kidney Journal | May 24, 2023 | Volume: 16 | Issue: 10 | Pages: 1691-1700

10.1093/ckj/sfad114 | PMID 37779848 Get It

ABSTRACT Background Autosomal dominant polycystic kidney disease (ADPKD) presents with variable disease severity and progression. Advanced imaging biomarkers may provide insights into cystic and non-cystic processes leading to kidney failure in different age groups. Methods This pilot study included 39 ADPKD patients with kidney failure, stratified into three age groups (<46, 46–56, >56 years old). Advanced imaging biomarkers were assessed using an automated instance cyst segmentation tool. The biomarkers were compared with an age- and sex-matched ADPKD cohort in early chronic kidney disease (CKD). Results Ht-total parenchymal volume correlated negatively with age at kidney failure. The median Ht-total parenchymal volume was significantly lower in patients older than 56 years. Cystic burden was significantly higher at time of kidney failure, especially in patients who reached it before age 46 years. The cyst index at kidney failure was comparable across age groups and Mayo Imaging Classes. Advanced imaging biomarkers showed higher correlation with Ht-total kidney volume in early CKD than at kidney failure. Cyst index and parenchymal index were relatively stable over 5 years prior to kidney failure, whereas Ht-total cyst volume and cyst parenchymal surface area increased significantly. Conclusion Age-related differences in advanced imaging biomarkers suggest variable pathophysiological mechanisms in ADPKD patients with kidney failure. Further studies are needed to validate the utility of these biomarkers in predicting disease progression and guiding treatment strategies.
Cardiac implantable electronic devices and outcomes in heart failure patients with syncope
Sriramoju, Anil , Tagle-Cornell, Maria Cecilia , Fariña, Juliana, Beirne, E , Fatunde, Olubadewa A. , Ko, N Ko, Shanbhag, Anusha , Barry, Timothy, Shen, W K, Rattanawong, Pattara , Chao, Chieh‐Ju , Farina, J, Koepke, L, Ko, Nway L. Ko

Mayo Clinic

Europace | May 24, 2023 | Volume: 25 | Issue: Supplement_1 | Pages: No page available

10.1093/europace/euad122.244 Get It

Abstract Funding Acknowledgements Type of funding sources: Private hospital(s). Main funding source(s): Mayo Clinic Background/Introduction Syncope is a common presentation in heart failure (HF) patients. However, the associations between syncope and prognosis in HF patients with the cardiac implantable electronic device (CIED) have not been demonstrated. It is unclear whether syncope increases all-cause mortality in HF patients with CIED. Purpose We aimed to examine the association between syncope and all-cause mortality in the largest cohort of HF with reduced ejection fraction (HFrEF), mid-ranged ejection fraction (HFmEF), and preserved ejection fraction (HFpEF) patients with and without CIED. Methods A retrospective cohort of patients with HF and syncope at our hospital between 2010 and 2015 were identified, and 1:1 propensity was matched with a control group of HF patients without syncope. A chart review was conducted. The multivariate Cox regression model was applied to estimate the association between syncope and the all-cause mortality endpoint. Results 3,449 HF patients were diagnosed with syncope (mean age, 72.8±14.5 years; 41.5% women), and the propensity-matched control HF patients without syncope (n=3,449) aged 72.8±14.3 years, and 42.5% women were selected. Cardiac implantable electronic devices were implanted more in HF patients with syncope (32.5% versus 13.7%, p<0.001). Implantable cardioverter defibrillators were implanted more in HF patients with syncope (15.6% versus 8.3%, p<0.001) as well as pacemakers (16.9% versus 7.5%, p<0.001) and cardiac resynchronization therapy devices (6.9% versus 4.8%, p=0.015). Among HF patients with CIED, syncope significantly increased the risk of all-cause mortality in HFrEF patients (hazard ratio [HR]=1.479, 95% confidence interval [CI]: 1.197-1.828, p<0.001) but not in HFpEF (HR=0.980, 95%CI: 0.793-1.210, p=0.849)(Figure 1). Syncope also tended to increase the risk of all-cause mortality in HFmEF patients with CIED but was not significant (HR=1.193, 95%CI: 0.762-1.865, p=0.762)(Figure 1). Among HF patients without CIED, syncope did not increase the risk of all-cause mortality in HFrEF (HR=0.923, 95%CI: 0.806-1.057, p=0.247), HFmEF (HR=1.074, 95%CI: 0.848-1.360, p=0.554), or HFpEF (HR=0.964, 95%CI: 0.883-1.052, p=0.406). Conclusions Syncope significantly increased the risk of all-cause mortality in HFrEF patients but not in HFmEF or HFpEF patients with CIED. The association of syncope and increased mortality in HFrEF patients with CIED suggests that syncope may be a marker and a factor of mortality and warrants further investigation.
Immune checkpoint inhibitor myocarditis with complete heart block: a case series
O’Shea, Molly , Karikalan, Suganya Arunachalam , Yusuf, Abdulkani , Nayak, Sandeep , Barry, Timothy, Shah, Sahrish, Karikalan, Suganya , Yusuf, A, Nayak, S, Masson, R, Masry, Hicham El

Mayo Clinic

Europace | May 24, 2023 | Volume: 25 | Issue: Supplement_1 | Pages: No page available

10.1093/europace/euad122.246 Get It

Abstract Funding Acknowledgements Type of funding sources: None. Background/Introduction Immune checkpoint inhibitor (ICI) myocarditis is a life-threatening condition characterized by lymphocytic myocardial infiltration[1]. Complete heart block (CHB) occurs in 15% of cases and is often fatal[2-4]. The nature and optimal management of this often-malignant condition is poorly understood[5]. Purpose This case series assesses prognostic factors associated with survival at 90 days among people with ICI myocarditis and CHB. Methods The electronic patient record system was used to identify patients admitted with ICI myocarditis. A two-physician review was used to assess the presence of ICI-associated CHB. Wilcoxon rank sum and Spearman’s rank correlation were used for categorical and quantitative variables respectively. Data was analysed using STATA/IC 16.1. The primary outcome was person-day survival 90 days after presenting symptom onset. Results Six patients were included in the final analysis. Mean survival was 47 person days. All had metastatic disease and presented 15 to 32 days after the first ICI infusion. All had muscle weakness. Other common self-symptoms were shortness of breath (4), blurred vision (4), double vision (3), collapse (3), and leg swelling (1). Proximal myopathy (2), fatigable myopathy (1), ptosis (3), and peripheral oedema (1) were present on examination. Raised troponin T and white blood cell count (WBC) were associated with 90-day survival (see Table 1). Nt-pro BNP, AST, and CK levels were raised in all patients. Two patients were tested for anti-striated muscle antibody titres, and both were strongly positive. Increase in QRS duration compared to baseline ECG was associated with lower survival at 90 days. Only one patient had CHB on admission. Steroid dose, IVIG, and plasmapheresis weren’t associated with survival. One patient declined device therapy. One declined permanent pacemaker (PPM) after insertion of transvenous pacemaker (TVP). Both died within 2 weeks. Three people underwent insertion of a transvenous pacemaker (TVP) followed by PPM insertion (table 2). All three eventually died within 100 days. One person received isoproterenol and immunosuppression as a bridge to PPM and survived. One patient was managed initially with TVP but subsequently declined PPM insertion. TVP removal resulted in CHB recurrence, and they died shortly after discharge. One person declined device therapy and died while receiving comfort care. Lead malfunction was frequent. One patient experienced bradycardia arrest with failure of a TVP lead to capture, while another experienced lead dislodgement. Conclusion CHB secondary to ICI is often fatal. It should be considered in patients presenting with symptoms of myositis, raised troponin and increased QRS duration. Despite a small sample size, this study identifies several prognostic factors which can guide both patients and physicians with decision-making. Larger studies are needed to better understand the role of device therapy in this population.
Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy
Lampert, Rachel , Ackerman, Michael J. , Marino, Bradley S. , Burg, Matthew M. , Ainsworth, Barbara E. , Tome, Maite , Abraham, Roselle, Balaji, Seshadri , Barth, Cheryl , Berul, Charles I. , Bos, Martijn, Cannom, David S. , Choudhury, Lubna , Concannon, Maryann, Cooper, Robert , Czosek, Richard J. , Dubin, Anne M. , Dziura, James, Eidem, Benjamin W., Etheridge, Susan P. , Geske, Jeffrey B. , Gray, Belinda , Lal, Ashwin K. , Ommen, Steven R., Saarel, Elizabeth V. , Simone, Laura, Tomaselli, Gordon F., Ware, James S. , Day, Sharlene M. , Abrahms, Dominic Jr, Ashley, Euan A. , Aziz, Peter F. , Batra, Anjan S. , Ferhaan, Ahmad, Gollob, Michael J., Kanter, Ronald J. , Li, Walter, Masri, Ahmad , Murphy, Ann Mooney, Popjes, Eric , Rao, Roopa S, Rosenthal, David N. , Semsarian, Chris, Shah, Maully J. , Tardif, Jill, Towbin, Jeffrey A. , Turer, Aslan T., Bos, J. Martijn , Eidem, Benjamin, Bos, Johan M , Dubin, Anne M , Ware, James S , Geske, Jeffrey B , Tome Esteban, Maria Teresa , Gray, Belinda , Salberg, Lisa , Ho, Carolyn Y. , Dziura, James, Emery, Michael S. , Estes, N.A. Mark , Hall, Kevin D. , Harmon, Kimberly G. , James, Cynthia A. , Law, Ian H. , Li, Fangyong , Link, Mark S. , McKenna, William J. , Molossi, Silvana M , Olshansky, Brian , Saberi, Sara , Zipes, Douglas P. , Cerrone, Marina , Colan, Steven D. , Erickson, Christopher, Ferhaan, Ahmad, Johnsrude, Christopher L. , Kannankeril, Prince J. , Murphy, Ann, Nandi, Deipanjan , Pérez, Marco , Perry, James C. , Rao, Roopa, Sanatani, Shubhayan , Skinner, Jonathan R. , Webster, Gregory , Wever‐Pinzon, Omar , Wong, Timothy C.

Mayo Clinic

JAMA Cardiology | May 17, 2023 | Volume: 8 | Issue: 6 | Pages: 595

10.1001/jamacardio.2023.1042 | PMID 37195701 Get It

Importance Whether vigorous intensity exercise is associated with an increase in risk of ventricular arrhythmias in individuals with hypertrophic cardiomyopathy (HCM) is unknown. Objective To determine whether engagement in vigorous exercise is associated with increased risk for ventricular arrhythmias and/or mortality in individuals with HCM. The a priori hypothesis was that participants engaging in vigorous activity were not more likely to have an arrhythmic event or die than those who reported nonvigorous activity. Design, Setting, and Participants This was an investigator-initiated, prospective cohort study. Participants were enrolled from May 18, 2015, to April 25, 2019, with completion in February 28, 2022. Participants were categorized according to self-reported levels of physical activity: sedentary, moderate, or vigorous-intensity exercise. This was a multicenter, observational registry with recruitment at 42 high-volume HCM centers in the US and internationally; patients could also self-enroll through the central site. Individuals aged 8 to 60 years diagnosed with HCM or genotype positive without left ventricular hypertrophy (phenotype negative) without conditions precluding exercise were enrolled. Exposures Amount and intensity of physical activity. Main Outcomes and Measures The primary prespecified composite end point included death, resuscitated sudden cardiac arrest, arrhythmic syncope, and appropriate shock from an implantable cardioverter defibrillator. All outcome events were adjudicated by an events committee blinded to the patient’s exercise category. Results Among the 1660 total participants (mean [SD] age, 39 [15] years; 996 male [60%]), 252 (15%) were classified as sedentary, and 709 (43%) participated in moderate exercise. Among the 699 individuals (42%) who participated in vigorous-intensity exercise, 259 (37%) participated competitively. A total of 77 individuals (4.6%) reached the composite end point. These individuals included 44 (4.6%) of those classified as nonvigorous and 33 (4.7%) of those classified as vigorous, with corresponding rates of 15.3 and 15.9 per 1000 person-years, respectively. In multivariate Cox regression analysis of the primary composite end point, individuals engaging in vigorous exercise did not experience a higher rate of events compared with the nonvigorous group with an adjusted hazard ratio of 1.01. The upper 95% 1-sided confidence level was 1.48, which was below the prespecified boundary of 1.5 for noninferiority. Conclusions and Relevance Results of this cohort study suggest that among individuals with HCM or those who are genotype positive/phenotype negative and are treated in experienced centers, those exercising vigorously did not experience a higher rate of death or life-threatening arrhythmias than those exercising moderately or those who were sedentary. These data may inform discussion between the patient and their expert clinician around exercise participation.
The Alzheimer's Disease Prediction Of Longitudinal Evolution (TADPOLE) Challenge: Results after 1 Year Follow-up
Bron, Esther E. , Toga, Arthur W. , Weiner, Michael W. , Barkhof, Frederik , Fox, Nick C. , Eshaghi, Arman , Toni, Tina, Salaterski, Marcin, Lunina, Veronika, Ansart, Manon , Lu, Pascal , Thompson, Wesley K., Nahon, Aviv, Levy, Yarden, Halbersberg, Dan, Cohen, Mariya, Liao, Huiling , Yu, Kaixian , Ismail, Aya, Wood, Timothy C. , Nguyen, Minh , Sun, Nanbo , Yeo, B.T. Thomas , Qi, Ke , Chen, Shiyang , Qiu, Deqiang , Buciuman, Ionut, Kelner, Alex, Rimocea, Denisa, Ourselin, Sébastien , Venkatraghavan, Vikram , Liu, Keli , Rabe, Christina, Manser, Paul T. , Howlett, James , Huang, Zhiyue , Mukherjee, Sach, Rouanet, Anaïs , Oriol, Javier de Velasco , Clemente, Edgar E. V., Estrada, Karol , Altmann, André , Stonnington, Cynthia M. , Wu, Jianfeng , Devadas, Vivek, Fourrier, Clémentine , Doshi, Jimit , Moore, Paul J. , Lyons, Terry , Ciszek, Robert, Jedynak, Bruno , Pandya, K., Engels, William R., Cole, Joseph B., Golland, Polina , Alexander, Daniel C. , Initiative, The Alzheimer's Disease Neuroimaging, Toga, Arthur W , Barkhof, Frederik , Fox, Nick C , Weiner, Michael W , Marinescu, Razvan Valentin , Oxtoby, Neil P. , Young, Alexandra L. , Durrleman, Stanley , Iddi, Samuel , Li, Dan , Donohue, Michael , Li, Tengfei , Zhu, Hongtu , Tamez‐Peña, José G. , Wood, Timothy, Bravo, Héctor Corrada , Feng, Jiashi , Chen, Gang , Qi, Ke, Pop, Raluca, Ghazi, Mostafa Mehdipour , Nielsen, Mads , Sørensen, Lauge , Hill, Steven M., Kiddle, Steven John , Taschler, Bernd , Tom, Brian D. M. , White, Simon Richard , Faux, Noel Garry , Sedai, Suman , Aksman, Leon , Wang, Yalin , Rakêt, Lars Lau , Sotiras, Aristeidis , Erus, Güray , Davatzikos, Christos , Vogel, Jacob W. , Doyle, Andrew , Tam, Angela , Diaz-Papkovich, Alex , Jammeh, Emmanuel , Koval, Igor , Gallacher, John , Tohka, Jussi , Pandya, Kruti, Bilgel, Murat , Engels, William, Cole, Joseph, Klein, Stefan , Initiative, The Alzheimer's Disease Neuroimaging

Mayo Clinic

Machine Learning for Biomedical Imaging | May 17, 2023 | Volume: 1 | Issue: December 2021 | Pages: 1-60

10.59275/j.melba.2021-2dcc Get It

Accurate prediction of progression in subjects at risk of Alzheimer's disease is crucial for enrolling the right subjects in clinical trials. However, a prospective comparison of state-of-the-art algorithms for predicting disease onset and progression is currently lacking. We present the findings of "The Alzheimer's Disease Prediction Of Longitudinal Evolution" (TADPOLE) Challenge, which compared the performance of 92 algorithms from 33 international teams at predicting the future trajectory of 219 individuals at risk of Alzheimer's disease. Challenge participants were required to make a prediction, for each month of a 5-year future time period, of three key outcomes: clinical diagnosis, Alzheimer's Disease Assessment Scale Cognitive Subdomain (ADAS-Cog13), and total volume of the ventricles. The methods used by challenge participants included multivariate linear regression, machine learning methods such as support vector machines and deep neural networks, as well as disease progression models. No single submission was best at predicting all three outcomes. For clinical diagnosis and ventricle volume prediction, the best algorithms strongly outperform simple baselines in predictive ability. However, for ADAS-Cog13 no single submitted prediction method was significantly better than random guesswork. Two ensemble methods based on taking the mean and median over all predictions, obtained top scores on almost all tasks. Better than average performance at diagnosis prediction was generally associated with the additional inclusion of features from cerebrospinal fluid (CSF) samples and diffusion tensor imaging (DTI). On the other hand, better performance at ventricle volume prediction was associated with inclusion of summary statistics, such as the slope or maxima/minima of patient-specific biomarkers. On a limited, cross-sectional subset of the data emulating clinical trials, performance of the best algorithms at predicting clinical diagnosis decreased only slightly (2 percentage points) compared to the full longitudinal dataset. The submission system remains open via the website https://tadpole.grand-challenge.org, while TADPOLE SHARE (https://tadpole-share.github.io/) collates code for submissions. TADPOLE's unique results suggest that current prediction algorithms provide sufficient accuracy to exploit biomarkers related to clinical diagnosis and ventricle volume, for cohort refinement in clinical trials for Alzheimer's disease. However, results call into question the usage of cognitive test scores for patient selection and as a primary endpoint in clinical trials.
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
Wang, Michael , Jurczak, Wojciech , Zinzani, Pier Luigi , Eyre, Toby A. , Cheah, Chan Y. , Ujjani, Chaitra S. , Koh, Youngil , Izutsu, Koji , Gerson, James N. , Flinn, Ian W. , Alencar, Alvaro J. , Ma, Shuo , Lewis, David , Patel, Krish , Maddocks, Kami J. , Lamanna, Nicole , Nagai, Hirokazu, Hernandez‐Ilizaliturri, Francisco J. , Kumar, Anita , Fenske, Timothy S. , Seymour, John F. , Nair, Binoj C., Tsai, Donald E. , Balbas, Minna, Walgren, Richard A., Abada, Paolo, Wang, Chunxiao , Zhao, Junjie, Mato, Anthony R. , Shah, Nirav N. , Wang, Michael L , Flinn, Ian W , Tessoulin, Benoit , Alencar, Alvaro J , Ma, Shuo , Lewis, David , Lech-Maranda, Ewa , Rhodes, Joanna , Patel, Krish , Lamanna, Nicole , Wang, Yucai , Tam, Constantine S , Munir, Talha , Kumar, Anita , Fenske, Timothy S , Seymour, John F , Zelenetz, Andrew D , Abada, Paolo , Mato, Anthony , Shah, Nirav N , Zinzani, Pier Luigi , Cheah, Chan Yoon , Izutsu, Koji , Jurczak, Wojciech , Lech‐Marańda, Ewa , Rhodes, Joanna , Wang, Yucai , Tam, Constantine S. , Zelenetz, Andrew D.

Mayo Clinic

Journal of Clinical Oncology | May 16, 2023 | Volume: 41 | Issue: 24 | Pages: 3988-3997

10.1200/jco.23.00562 | PMID 37192437 Get It

PURPOSE Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi) pretreated mantle-cell lymphoma (MCL), a population with poor prognosis. METHODS Patients with cBTKi pretreated relapsed/refractory (R/R) MCL received pirtobrutinib monotherapy in a multicenter phase I/II trial (BRUIN; ClinicalTrials.gov identifier: NCT03740529 ). Efficacy was assessed in the first 90 consecutively enrolled patients who met criteria for inclusion in the primary efficacy cohort. The primary end point was overall response rate (ORR). Secondary end points included duration of response (DOR) and safety. RESULTS The median patient age was 70 years (range, 46-87), the median prior lines of therapy was 3 (range, 1-8), 82.2% had discontinued a prior cBTKi because of disease progression, and 77.8% had intermediate- or high-risk simplified MCL International Prognostic Index score. The ORR was 57.8% (95% CI, 46.9 to 68.1), including 20.0% complete responses (n = 18). At a median follow-up of 12 months, the median DOR was 21.6 months (95% CI, 7.5 to not reached). The 6- and 12-month estimated DOR rates were 73.6% and 57.1%, respectively. In the MCL safety cohort (n = 164), the most common treatment-emergent adverse events (TEAEs) were fatigue (29.9%), diarrhea (21.3%), and dyspnea (16.5%). Grade ≥3 TEAEs of hemorrhage (3.7%) and atrial fibrillation/flutter (1.2%) were less common. Only 3% of patients discontinued pirtobrutinib because of a treatment-related adverse event. CONCLUSION Pirtobrutinib is a first-in-class novel noncovalent (reversible) BTKi and the first BTKi of any kind to demonstrate durable efficacy after prior cBTKi therapy in heavily pretreated R/R MCL. Pirtobrutinib was well tolerated with low rates of treatment discontinuation because of toxicity.
A Radiologist’s Guide to the 2021 WHO Central Nervous System Tumor Classification: Part 2—Newly Described and Revised Tumor Types
Guérin, J. , Kaufmann, Timothy J. , Eckel, Laurence J. , Vaubel, Rachael A. , Giannini, Caterina , Johnson, Derek R. , Guerin, Julie B , Vaubel, Rachael A , Giannini, Caterina , Johnson, Derek R , Kaufmann, Timothy J , Morris, Jonathan M.

Mayo Clinic

Radiology | May 16, 2023 | Volume: 307 | Issue: 5 | Pages: No page available

10.1148/radiol.221885 | PMID 37191486 Get It

Next-Generation Boron Drugs and Rational Translational Studies Driving the Revival of BNCT
Seneviratne, Danushka S. , Mackeyev, Yuri , Malouff, Timothy D. , Krishnan, Sunil , Mackeyev, Yuri , Krishnan, Sunil , Seneviratne, Danushka , Saifi, Omran

Mayo Clinic

Cells | May 16, 2023 | Volume: 12 | Issue: 10 | Pages: 1398

10.3390/cells12101398 | PMID 37408232 Get It

BNCT is a high-linear-energy transfer therapy that facilitates tumor-directed radiation delivery while largely sparing adjacent normal tissues through the biological targeting of boron compounds to tumor cells. Tumor-specific accumulation of boron with limited accretion in normal cells is the crux of successful BNCT delivery. Given this, developing novel boronated compounds with high selectivity, ease of delivery, and large boron payloads remains an area of active investigation. Furthermore, there is growing interest in exploring the immunogenic potential of BNCT. In this review, we discuss the basic radiobiological and physical aspects of BNCT, traditional and next-generation boron compounds, as well as translational studies exploring the clinical applicability of BNCT. Additionally, we delve into the immunomodulatory potential of BNCT in the era of novel boron agents and examine innovative avenues for exploiting the immunogenicity of BNCT to improve outcomes in difficult-to-treat malignancies.
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
Zayac, Adam , Landsburg, Daniel J. , Hughes, Mitchell E. , Bock, Allison M. , Nowakowski, Grzegorz S. , Ayers, Emily C. , Girton, Mark , Hu, Marie , Beckman, Amy , Li, Shaoying , Chang, Julie , Stepanovic, Adam , Sandoval‐Sus, Jose , Ansari‐Lari, M. Ali, Kothari, Shalin , Kress, Anna, Xu, Mina L. , Torka, Pallawi , Smith, Stephen D. , Naresh, Kikkeri N. , Karimi, Yasmin , Farooq, Umar , Saad, Mahak, Evens, Andrew M. , Pandya, Karan, Naik, Seema , Kamdar, Manali , Haverkos, Bradley M. , Oh, Timothy S. , Nutsch, Heather, Rubinstein, P , Chaudhry, Amina, Zayac, Adam S , Medeiros, L Jeffrey , Kurt, Habibe , Torka, Pallawi , Sundaram, Suchitra , Smith, Stephen D , Naresh, Kikkeri N , Karimi, Yasmin H , Epperla, Narendranath , Bond, David A , Farooq, Umar , Evens, Andrew M , Naik, Seema G , Kamdar, Manali , Haverkos, Bradley M , Karmali, Reem , Oh, Timothy S , Vose, Julie , Rubinstein, Paul G , Olszewski, Adam J , Landsburg, Daniel J , Hu, Marie , Li, Shaoying , Girton, Mark , Medeiros, L. Jeffrey , Kurt, Habibe , Epperla, Narendranath , Bond, David A. , Karmali, Reem , Vose, Julie M. , Chaudhry, Amina, Olszewski, Adam J.

Mayo Clinic

Blood Advances | May 12, 2023 | Volume: 7 | Issue: 21 | Pages: 6381-6394

10.1182/bloodadvances.2023009731 | PMID 37171397 Get It

Abstract In this multi-institutional retrospective study, we examined the characteristics and outcomes of 160 patients with high-grade B-cell lymphoma, not otherwise specified (HGBL-NOS)—a rare category defined by high-grade morphologic features and lack of MYC rearrangements with BCL2 and/or BCL6 rearrangements ("double hit"). Our results show that HGBL-NOS tumors are heterogeneous: 83% of patients had a germinal center B-cell immunophenotype, 37% a dual-expressor immunophenotype (MYC and BCL2 expression), 28% MYC rearrangement, 13% BCL2 rearrangement, and 11% BCL6 rearrangement. Most patients presented with stage IV disease, a high serum lactate dehydrogenase, and other high-risk clinical factors. Most frequent first-line regimens included dose-adjusted cyclophosphamide, doxorubicin, vincristine, and etoposide, with rituximab and prednisone (DA-EPOCH-R; 43%); rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; 33%); or other intensive chemotherapy programs. We found no significant differences in the rates of complete response (CR), progression-free survival (PFS), or overall survival (OS) between these chemotherapy regimens. CR was attained by 69% of patients. PFS at 2 years was 55.2% and OS was 68.1%. In a multivariable model, the main prognostic factors for PFS and OS were poor performance status, lactate dehydrogenase >3 × upper limit of normal, and a dual-expressor immunophenotype. Age >60 years or presence of MYC rearrangement were not prognostic, but patients with TP53 alterations had a dismal PFS. Presence of MYC rearrangement was not predictive of better PFS in patients treated with DA-EPOCH-R vs R-CHOP. Improvements in the diagnostic criteria and therapeutic approaches beyond dose-intense chemotherapy are needed to overcome the unfavorable prognosis of patients with HGBL-NOS.